Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Nivolumab potentially superior to standard chemo in advanced melanoma

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab potentially superior to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

Targeted therapy for iodine-refractory thyroid cancer

Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan

$Targeted therapy for iodine-refractory thyroid cancer ( Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan )$

Questions raised about the future of lung cancer vaccination?

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Questions raised about the future of lung cancer vaccination? ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

PD-L1 protein a possible immunotherapy target in mesothelioma

Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland

PD-L1 protein a possible immunotherapy target in mesothelioma ( Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland )

Improved response rate and survival with dabrafenib plus trametinib versus...

Dr Caroline Robert - Gustave Roussy, Villejuif, France

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )

Vemurafenib plus cobimetinib achieves significant progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Nivolumab shows signs of superior response rate compared to standard chemo in...

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

Improvements in progression free survival for patients with metastatic head and...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Molecular targeting in cancer and the impact on personalised medicine

Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer...

Molecular targeting in cancer and the impact on personalised medicine ( Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK

Cediranib and chemo combo improves PFS for metastatic cervical cancer ( Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK )

Phase III trial results raise questions about the future of lung cancer...

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Phase III trial results raise questions about the future of lung cancer vaccination ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

More from ecancer